Clinical Trial Update: A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC) [Phase 3]

View source ↗

Summary

A Phase 3 trial in first-line extensive-stage small-cell lung cancer compares Tarlatamab plus Durvalumab with Carboplatin and Etoposide to Durvalumab with Carbo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extensive-stage Small Cell Lung Cancer
• Small Cell Lung Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• Durvalumab (durvalumab)
• Etoposide (Etoposide)
• Tarlatamab

Snippet

Sponsor: Amgen | Conditions: Small-cell Lung Cancer, Extensive Stage Small-cell Lung Cancer | Phase 3 | Status: RECRUITING